(PRGO) Perrigo - Ratings and Ratios

Exchange: NYSE • Country: Ireland • Currency: USD • Type: Common Stock • ISIN: IE00BGH1M568

OTC Medicines, Infant Nutrition, Oral Care, Skin Care, Vitamins

Stock: Pharmaceuticals
Age 34.1y

MCap 2,068m
Avg Vol 2.27M (34.3M USD)

Beta 0.682
Volatility 34.18%

EPS (Earnings per Share)

EPS CAGR: -40.12%
EPS Trend: -8.4%

Last SUE: -3.68
Qual. Beats: 0

Revenue

Rev. CAGR: -1.52%
Rev. Trend: -45.7%

Last SUE: -2.23
Qual. Beats: 0

Dividends

Dividend Yield	5.51%
Yield on Cost 5y	3.12%
Yield CAGR 5y	4.84%
Payout Consistency	100.0%
Payout Ratio	49.8%

Risk via 5d forecast
Volatility	34.2%
Value at Risk 5%th	48.7%
Relative Tail Risk	-13.39%

Reward TTM
Sharpe Ratio	-0.77
Alpha	-46.77
CAGR/Max DD	-0.34

Character TTM
Hurst Exponent	0.811
Beta	0.682
Beta Downside	0.678

Drawdowns 3y
Max DD	66.45%
Mean DD	26.18%
Median DD	26.59%

Description: PRGO Perrigo January 11, 2026

Perrigo Company plc (NYSE: PRGO) is a Dublin-based manufacturer of over-the-counter (OTC) health and wellness products sold in the United States, Europe and other international markets. The firm operates through two segments-Consumer Self-Care Americas and Consumer Self-Care International-and offers a broad portfolio that includes upper-respiratory remedies, infant nutrition, digestive health, pain-and-sleep aids, oral-care accessories, smoking-cessation aids, skin-care, women’s health items, vitamins, minerals, supplements, and a niche rare-diseases business. Its brands such as Coldrex, Nasonex, Plackers, Good Sense and Mederma are distributed via drugstores, supermarkets, mass-merchandise chains, e-commerce platforms and wholesale channels, and the company also provides contract-manufacturing services.

Key recent metrics: FY 2023 revenue was approximately $2.5 billion, with an adjusted operating margin of roughly 8 %-down modestly from prior years as input-cost inflation and competitive pricing pressure intensified. The OTC market in the U.S. is projected to grow 3-4 % CAGR through 2028, driven by an aging population and increased consumer preference for self-managed care, which supports Perrigo’s focus on high-margin niche categories such as rare-disease therapies and premium oral-care accessories. A notable sector driver is the accelerating shift to online retail; e-commerce now accounts for about 12 % of Perrigo’s total sales, a share that is expected to rise as digital distribution channels expand.

For a deeper, data-rich view of Perrigo’s valuation and risk profile, you might explore the company’s profile on ValueRay.

Piotroski VR‑10 (Strict, 0-10) 4.5

Net Income: -51.8m TTM > 0 and > 6% of Revenue
FCF/TA: 0.03 > 0.02 and ΔFCF/TA 1.34 > 1.0
NWC/Revenue: 40.49% < 20% (prev 51.40%; Δ -10.90% < -1%)
CFO/TA 0.04 > 3% & CFO 375.7m > Net Income -51.8m
Net Debt (3.39b) to EBITDA (611.5m): 5.55 < 3
Current Ratio: 2.51 > 1.5 & < 3
Outstanding Shares: last quarter (138.9m) vs 12m ago 1.02% < -2%
Gross Margin: 35.46% > 18% (prev 0.36%; Δ 3510 % > 0.5%)
Asset Turnover: 40.23% > 50% (prev 39.20%; Δ 1.03% > 0%)
Interest Coverage Ratio: 1.59 > 6 (EBITDA TTM 611.5m / Interest Expense TTM 175.7m)

Altman Z'' 1.40

A: 0.17 (Total Current Assets 2.88b - Total Current Liabilities 1.15b) / Total Assets 10.08b
B: -0.22 (Retained Earnings -2.26b / Total Assets 10.08b)
C: 0.03 (EBIT TTM 279.6m / Avg Total Assets 10.64b)
D: 0.79 (Book Value of Equity 4.45b / Total Liabilities 5.64b)
Altman-Z'' Score: 1.40 = BB

Beneish M -3.13

DSRI: 0.88 (Receivables 675.6m/785.9m, Revenue 4.28b/4.39b)
GMI: 1.02 (GM 35.46% / 36.07%)
AQI: 1.06 (AQ_t 0.61 / AQ_t-1 0.57)
SGI: 0.97 (Revenue 4.28b / 4.39b)
TATA: -0.04 (NI -51.8m - CFO 375.7m) / TA 10.08b)
Beneish M-Score: -3.13 = AA

ValueRay F-Score (Strict, 0-100) 47.29

1. Piotroski: 4.50pt
2. FCF Yield: 4.97%
3. FCF Margin: 6.34%
4. Debt/Equity: 0.86
5. Debt/Ebitda: 5.55
6. ROIC - WACC: -1.50%
7. RoE: -1.18%
8. Revenue Trend: -45.69%
9. EPS Trend: -8.40%

What is the price of PRGO shares?

As of January 23, 2026, the stock is trading at USD 15.08 with a total of 2,488,834 shares traded.
Over the past week, the price has changed by -0.59%, over one month by +12.12%, over three months by -28.81% and over the past year by -33.75%.

Is PRGO a buy, sell or hold?

Perrigo has received a consensus analysts rating of 3.80. Therefor, it is recommend to hold PRGO.

Strong Buy: 1
Buy: 2
Hold: 2
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the PRGO price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	21	39.3%
Analysts Target Price	21	39.3%
ValueRay Target Price	13.1	-13.4%

PRGO Fundamental Data Overview January 18, 2026

P/E Forward = 5.3677
P/S = 0.4831
P/B = 0.4652
P/EG = 1.1418
Revenue TTM = 4.28b USD
EBIT TTM = 279.6m USD
EBITDA TTM = 611.5m USD
Long Term Debt = 3.61b USD (from longTermDebt, last quarter)
Short Term Debt = 65.0m USD (from shortTermDebt, last quarter)
Debt = 3.83b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.39b USD (from netDebt column, last quarter)
Enterprise Value = 5.46b USD (2.07b + Debt 3.83b - CCE 432.1m)
Interest Coverage Ratio = 1.59 (Ebit TTM 279.6m / Interest Expense TTM 175.7m)
EV/FCF = 20.13x (Enterprise Value 5.46b / FCF TTM 271.4m)
FCF Yield = 4.97% (FCF TTM 271.4m / Enterprise Value 5.46b)
FCF Margin = 6.34% (FCF TTM 271.4m / Revenue TTM 4.28b)
Net Margin = -1.21% (Net Income TTM -51.8m / Revenue TTM 4.28b)
Gross Margin = 35.46% ((Revenue TTM 4.28b - Cost of Revenue TTM 2.76b) / Revenue TTM)
Gross Margin QoQ = 36.14% (prev 34.36%)
Tobins Q-Ratio = 0.54 (Enterprise Value 5.46b / Total Assets 10.08b)
Interest Expense / Debt = 1.41% (Interest Expense 54.0m / Debt 3.83b)
Taxrate = 43.30% (9.70m / 22.4m)
NOPAT = 158.5m (EBIT 279.6m * (1 - 43.30%))
Current Ratio = 2.51 (Total Current Assets 2.88b / Total Current Liabilities 1.15b)
Debt / Equity = 0.86 (Debt 3.83b / totalStockholderEquity, last quarter 4.45b)
Debt / EBITDA = 5.55 (Net Debt 3.39b / EBITDA 611.5m)
Debt / FCF = 12.51 (Net Debt 3.39b / FCF TTM 271.4m)
Total Stockholder Equity = 4.40b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.49% (Net Income -51.8m / Total Assets 10.08b)
RoE = -1.18% (Net Income TTM -51.8m / Total Stockholder Equity 4.40b)
RoCE = 3.49% (EBIT 279.6m / Capital Employed (Equity 4.40b + L.T.Debt 3.61b))
RoIC = 1.97% (NOPAT 158.5m / Invested Capital 8.04b)
WACC = 3.48% (E(2.07b)/V(5.89b) * Re(8.43%) + D(3.83b)/V(5.89b) * Rd(1.41%) * (1-Tc(0.43)))
Discount Rate = 8.43% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 81.65 | Cagr: 0.74%
[DCF Debug] Terminal Value 86.89% ; FCFF base≈223.5m ; Y1≈236.9m ; Y5≈281.6m
Fair Price DCF = 35.98 (EV 8.35b - Net Debt 3.39b = Equity 4.95b / Shares 137.6m; r=5.90% [WACC]; 5y FCF grow 6.59% → 2.90% )
EPS Correlation: -8.40 | EPS CAGR: -40.12% | SUE: -3.68 | # QB: 0
Revenue Correlation: -45.69 | Revenue CAGR: -1.52% | SUE: -2.23 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.65 | Chg30d=-0.050 | Revisions Net=+1 | Analysts=1
EPS next Year (2026-12-31): EPS=2.72 | Chg30d=-0.142 | Revisions Net=-2 | Growth EPS=-2.0% | Growth Revenue=-1.5%

Additional Sources for PRGO Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle